Micafungin

Candidemia, prophylaxis of Esophageal candidiasis, Aspergillosis + 10 more

Treatment

11 FDA approvals

20 Active Studies for Micafungin

What is Micafungin

Micafungin

The Generic name of this drug

Treatment Summary

Micafungin is a medication used to treat fungal infections. It works by blocking the production of an essential component of the cell wall of fungi, called 1,3-beta-D-glucan.

Mycamine

is the brand name

Micafungin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Mycamine

Micafungin

2005

23

Approved as Treatment by the FDA

Micafungin, otherwise known as Mycamine, is approved by the FDA for 11 uses including Candidiasis and Systemic candidiasis .

Candidiasis

Systemic candidiasis

Meningoencephalitis

prophylaxis of Candida Infections

Bone Marrow Transplant

Candidemia

Peritonitis

Yeast Infection

Meningoencephalitis

Esophageal Candidiasis

Abscess

Effectiveness

How Micafungin Affects Patients

Micafungin, formerly known as FK463, is a medicine that fights off fungal infections. It works by blocking an enzyme in the fungus that helps build its cell wall. Depending on how much of the medicine is taken, it can either stop the fungus from growing (fungistatic) or kill it (fungicidal). Micafungin can be taken with other medicines, such as HIV drugs and transplant medicines.

How Micafungin works in the body

Micafungin prevents fungi from forming cell walls by blocking a compound, called beta-1,3-D-glucan synthase, that the fungi needs to build the walls. This compound isn't found in humans, so our cells are not affected.

When to interrupt dosage

The recommended quantity of Micafungin is contingent upon the identified condition, which may include Infections, Fungal, Candida (fungus) and Abscesses. The amount likewise varies as per the technique of delivery (e.g. Injection, powder, lyophilized, for solution - Intravenous or Intravenous) featured in the table beneath.

Condition

Dosage

Administration

prophylaxis of Esophageal candidiasis

, 50.0 mg, 100.0 mg, 20.0 mg/mL, 10.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL

, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Aspergillosis

, 50.0 mg, 100.0 mg, 20.0 mg/mL, 10.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL

, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

prophylaxis of moderate Pneumocystis pneumonia

, 50.0 mg, 100.0 mg, 20.0 mg/mL, 10.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL

, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Yeast Infection

, 50.0 mg, 100.0 mg, 20.0 mg/mL, 10.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL

, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

prophylaxis of Candida Infections

, 50.0 mg, 100.0 mg, 20.0 mg/mL, 10.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL

, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

HIV Positive

, 50.0 mg, 100.0 mg, 20.0 mg/mL, 10.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL

, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Abscess

, 50.0 mg, 100.0 mg, 20.0 mg/mL, 10.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL

, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

HIV

, 50.0 mg, 100.0 mg, 20.0 mg/mL, 10.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL

, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Esophageal Candidiasis

, 50.0 mg, 100.0 mg, 20.0 mg/mL, 10.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL

, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Bone Marrow Transplant

, 50.0 mg, 100.0 mg, 20.0 mg/mL, 10.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL

, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Peritonitis

, 50.0 mg, 100.0 mg, 20.0 mg/mL, 10.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL

, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Meningoencephalitis

, 50.0 mg, 100.0 mg, 20.0 mg/mL, 10.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL

, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Candidemia

, 50.0 mg, 100.0 mg, 20.0 mg/mL, 10.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL

, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Warnings

Micafungin Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

There are 16 known major drug interactions with Micafungin.

Common Micafungin Drug Interactions

Drug Name

Risk Level

Description

(R)-warfarin

Moderate

The therapeutic efficacy of (R)-warfarin can be increased when used in combination with Micafungin.

(S)-Warfarin

Moderate

The therapeutic efficacy of (S)-Warfarin can be increased when used in combination with Micafungin.

4-hydroxycoumarin

Moderate

The therapeutic efficacy of 4-hydroxycoumarin can be increased when used in combination with Micafungin.

Acenocoumarol

Moderate

The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Micafungin.

Clorindione

Moderate

The therapeutic efficacy of Clorindione can be increased when used in combination with Micafungin.

Micafungin Toxicity & Overdose Risk

The toxic dose of Diflucan for rats is 125mg/kg. In dogs, the toxic dose is higher than 200mg/kg. So far, no reports of overdose have been made. In clinical trials, adults have taken up to 8mg/kg of Diflucan per day with no severe side effects. The lowest dose that could be fatal to rats is 125mg/kg, which is 8.1 times the usual dose given to humans with esophageal candidiasis.

Micafungin Novel Uses: Which Conditions Have a Clinical Trial Featuring Micafungin?

459 active experiments are being conducted to assess the suitability of Micafungin for Candida (fungus), Abscesses and Peritonitis treatment.

Condition

Clinical Trials

Trial Phases

HIV

153 Actively Recruiting

Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4, Early Phase 1

HIV Positive

0 Actively Recruiting

Esophageal Candidiasis

0 Actively Recruiting

Aspergillosis

0 Actively Recruiting

Peritonitis

0 Actively Recruiting

prophylaxis of Candida Infections

0 Actively Recruiting

Bone Marrow Transplant

27 Actively Recruiting

Not Applicable, Phase 2, Early Phase 1, Phase 1

Yeast Infection

0 Actively Recruiting

Meningoencephalitis

0 Actively Recruiting

Abscess

0 Actively Recruiting

prophylaxis of Esophageal candidiasis

0 Actively Recruiting

prophylaxis of moderate Pneumocystis pneumonia

0 Actively Recruiting

Candidemia

3 Actively Recruiting

Phase 3, Phase 2

Patient Q&A Section about micafungin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long do you take micafungin?

"In patients who were successfully treated with micafungin, the average duration of therapy was 15 days, with a range of 10 to 30 days."

Answered by AI

What is micafungin used for?

"Micafungin is used to treat candidemia, acute disseminated candidiasis, candida peritonitis and abscess, and esophageal candidiasis."

Answered by AI

Is micafungin an antibiotic?

"Micafungin sodium is an antifungal medication used to treat and prevent infections caused by the Candida fungus."

Answered by AI

What kind of drug is micafungin?

"This medication can be used to treat a variety of fungal infections and to prevent fungal infections in patients who are going through a stem cell transplant. Micafungin works by stopping the growth of fungi and belongs to a class of drugs known as echinocandins."

Answered by AI

Clinical Trials for Micafungin

Image of New Jersey Community Research Initiative in Newark, United States.

AI-DBT for Suicide Prevention in HIV/AIDS

18+
All Sexes
Newark, NJ

One in four older persons living with HIV/AIDS (PLWHA) report at least one suicide attempt in their lifetime, and the risk for death by suicide is 100 times higher in PLWHA than in the general population. Currently, there are no behavioral interventions that specifically address suicide prevention for older PLWHA, despite their unique biopsychosocial and structural risk factors. Through this work, investigators will adapt Dialectical Behavior Therapy, an evidence-based intervention for suicide prevention, for patients with PLWHA to be delivered by an AI-powered conversational Agent developed by our industry partner, Empower Health. Investigators will then pilot test the feasibility, usability, acceptability and preliminary efficacy to improve self-efficacy to manage negative emotions in n=50 older adults living with HIV/AIDS.

Recruiting
Has No Placebo

New Jersey Community Research Initiative (+1 Sites)

Elissa Kozlov, PhD

Image of George Washington University Emergency Department in Washington D.C., United States.

Decision Support Tool for HIV Prevention

18+
All Sexes
Washington D.C., United States

This project will explore the development of a personalized decision support tool to assist with pre-exposure prophylaxis (PrEP) initiation and persistence among patients identified in the emergency department (ED) and urgent care settings as PrEP eligible. First, the investigators will use a sequence of validated implementation science methodologies to develop and validate a decision support tool designed to optimize PrEP persistence by strengthening self-efficacy by addressing the multifaceted medical and social needs of the individual patient. The investigators will then test the preliminary effectiveness of this tool through a pilot stepped wedge implementation trial in two EDs and an urgent care in Baltimore, MD and Washington, DC among 120 PrEP eligible patients to determine PrEP initiation, linkage to care, persistence, and adherence rates.

Phase 1
Waitlist Available

George Washington University Emergency Department (+1 Sites)

Image of The University of Alabama at Birmingham in Birmingham, United States.

Behavioral vs Mindfulness Treatments for Insomnia in HIV

50 - 99
All Sexes
Birmingham, AL

The goal of this clinical trial is to examine the effects of a telephone-delivered Brief Behavioral Treatment Insomnia (BBTI) versus a Brief Mindfulness Treatment (BMT) on cognitive and sleep outcomes in older adults with HIV. The main questions it aims to answer are: What are the effects of BBTI vs BMT on self-reported and observed sleep outcomes in older adults with HIV and insomnia up to 1-year post-intervention? What are the effects of BBTI vs BMT on self-reported and observed cognitive comes in older adults with HIV and insomnia up to 1-year post-intervention? What is the association between Alzheimer's Disease biomarkers and sleep and cognitive outcomes in older adults with HIV receiving BBTI vs BMT? Participants will: * Complete 4 weeks of telephone-delivered BBTI or BMT * Attend baseline, post-intervention, and 1-year post in-person visits for sleep and cognitive assessments * Have blood collected at all three time points

Waitlist Available
Has No Placebo

The University of Alabama at Birmingham (+1 Sites)

Dr. Shameka L Cody, PhD, AGNP-C, PMHNP-BC, FAAN

Image of University of Alabama at Birmingham in Birmingham, United States.

Olfactory Training for HIV

18+
All Sexes
Birmingham, AL

The goal of this study is to examine two types of olfactory interventions (olfactory training vs overnight odor diffuser) in adults with HIV. The two research questions are: 1. Determine if participants find the intervention acceptable and assess feasibility of the study. 2. Determine if the intervention improves olfactory function and cognitive function. Participants will come to our office and be administered the baseline battery of questions including olfactory and cognitive performance tests. Then they will be randomized and sent home with one of the two interventions (below) in which they will engage in it for 8 weeks, after which they come back to our office for the posttest battery of questions including olfactory and cognitive performance test. 1. Olfactory Training at Home -- 4 scents in which they will smell twice a day for 8 weeks. 2. Overnight Diffuser Group -- a single scent diffuser that participants will turn on while they sleep and use for 8 weeks.

Phase < 1
Waitlist Available

University of Alabama at Birmingham

Have you considered Micafungin clinical trials?

We made a collection of clinical trials featuring Micafungin, we think they might fit your search criteria.
Go to Trials
Image of University of North Carolina in Chapel Hill, United States.

MGD020 + MGD014 for HIV

18 - 65
All Sexes
Chapel Hill, NC

This research study aims to find out how safe and well tolerated the experimental study drugs are when given to persons with HIV (PWH) taking antiretroviral therapy (ART). The study treatments are MGD014 and MGD020, which are two antibodies developed specifically for HIV, and Vorinostat, an oral medication to help expose HIV in cells to the antibodies. The study will measure the impact of study treatment on non-active HIV in cells, and how long MGD014 and MGD020 stay in the body after they are given. In this study, participants will be randomly assigned to one of three groups. All participants receive MGD014 and MGD020, given sequentially as infusions through an IV for 4 doses. Participants in one group (group A) receive only MGD014 and MGD020. Participants in another group (group B) will stop taking their ART therapy for up to 8 weeks (a temporary treatment interruption (TTI)) while receiving MGD014 and MGD020. Participants in the third group (group C) receive Vorinostat in addition to MGD014 and MGD020. Total time of participation is about 8 months and involves 13 or 18 visits, depending on group assignment.

Phase 1
Recruiting

University of North Carolina

Cynthia L. Gay, MD

Image of Center on Substance Use and Health in San Francisco, United States.

CHAMPION Intervention for Pre-exposure Prophylaxis Adherence

18 - 40
Male
San Francisco, CA

The goal of this randomized controlled trial is to pilot test new mobile health (mHealth) interventions to improve PrEP adherence among HIV-negative men who have sex with men (MSM) with mild to moderate methamphetamine use disorder (MUD). The CHAMPION intervention combines two mHealth tools-PrEPAPP and CBT4CBT-to address both HIV prevention and MUD treatment needs in this population. The study's specific aims are: * To evaluate the feasibility and acceptability of the CHAMPION intervention based on treatment retention and engagement rates. * To examine the preliminary efficacy the CHAMPION intervention to improve PrEP adherence, as measured by dried blood spot (DBS) tests compared to the waitlist control group.

Waitlist Available
Has No Placebo

Center on Substance Use and Health

Glenn-Milo Santos, PhD, MPH

Have you considered Micafungin clinical trials?

We made a collection of clinical trials featuring Micafungin, we think they might fit your search criteria.
Go to Trials
Image of UCSF in San Francisco, United States.

N-803 for HIV

18 - 70
All Sexes
San Francisco, CA

Even though HIV medicine stops the virus from making more copies of itself, the virus remains in the body by hiding inside of immune cells. This hidden virus is referred to as the "latent reservoir." Researchers on this team are studying whether stimulating the immune system can change the nature of the latent reservoir and if this could help people control HIV without the need to take regular HIV medicine. This study is testing a drug called N-803. N-803 is also known as Interleukin-15 or "IL-15", a powerful and long lasting protein that can affect the immune system by stimulating immune cells such as CD8+ T cells and natural killer (NK) cells. CD8+ T cells and NK cells are both crucial for eliminating infected cells. The drug is FDA-approved for the treatment of bladder cancer, but in this study the drug is being used experimentally for HIV.

Phase 2
Waitlist Available

UCSF

Have you considered Micafungin clinical trials?

We made a collection of clinical trials featuring Micafungin, we think they might fit your search criteria.
Go to Trials